MADISON, Wis., Oct. 28, 2014 /PRNewswire/ -- Allovate, LLC, has signed an agreement with Restore Health, a company specializing in personalized medicine, for the exclusive rights to provide Allerdent™, a new personalized therapeutic toothpaste system for people suffering from allergic rhinitis. Allerdent™ is designed for daily use as part of a normal tooth-brushing regimen and enables allergy sufferers to incorporate immunotherapeutic allergy treatment into their routine activity. Impetus for this proprietary innovation came from the high drop-out rates of people undergoing other forms of immunotherapy. The goal of incorporating the allergy treatment into the daily activity of brushing one's teeth is to increase adherence and create more effective outcomes. This novel treatment method is available by prescription.
Shara Rudner, RPh., FIACP, FACA, Director, Clinical Trials Group for Restore Health, partnered with the research team that developed the new toothpaste delivery system. The research results were published in the July/August 2014 issue: International Journal of Pharmaceutical Compounding. "The research shows that using a toothpaste delivery system to treat patients with seasonal allergies is very promising," said Dr. Rudner. William Reisacher, MD, FACS, FAAOA, a faculty otolaryngic allergist at Weill-Cornell Medical College who co-authored the study with Rudner, added, "This novel approach to immunotherapy addresses the underlying cause of allergies without disrupting a normal lifestyle."
Allovate, LLC is a specialty biopharmaceutical company that specializes in allergen-specific immunotherapy for treating allergic diseases.
Under the agreement, Restore Health has limited exclusivity as the sole servicing agent for Allerdent™. The system, Allerdent™, was recently featured on CBS News as another treatment option for physicians to prescribe to their patients who may be using prescribed or over-the-counter medicines to relieve seasonal allergy symptoms.
"Our agreement to provide Allerdent™ system will ensure our customers have immediate access to this new treatment option," said Murray I. Firestone, Ph.D., President of Restore Health. "Restore is always working to accelerate the availability of novel therapies, from 'bench to bedside'."
CONTACT: Jessica Reilly, 800-558-7046, email@example.com
About Restore Health
Restore Health is the first trusted national brand wholly dedicated to bringing personalized and specialty medicines to healthcare providers throughout the United States. Its unique full-service solution offers physicians integrated support of custom pharmacy, diagnostic laboratory, and clinical liaison personnel. RestoreDirect is the company's proprietary I.T. platform, a cloud-based, HIPAA-compliant, enterprise resource planning (ERP) software suite. It was originally conceived nearly a decade ago and designed to meet the unique, business-critical requirements of a specialty compounding pharmacy operating in the personalized medicine space. Mirroring the growth of Restore Health and its creation of a trusted national brand, the RestoreDirect suite of integrated business applications has expanded to support Restore's remote sites and external trading partners through the full spectrum of secure transactions. Since 1982, Restore Health has established a reputation among physicians for providing personalized medications and guidance that truly make a difference in their patients' lives.
About Allovate, LLC
Allovate, LLC is a specialty biopharmaceutical company in New York City that is developing improved approaches to allergen-specific immunotherapy for the treatment of allergic diseases. Allergic diseases affect more than 25% of the global industrial population, at an annual cost in excess of $33 billion in the US alone. There is an enormous and growing unmet need for treatment options that modify the underlying disease rather than treating the symptoms alone. Allovate's mission is to expand the use of immunotherapy among the millions of allergy sufferers by developing products that are safer, more effective, and easier to administer. Allovate's premiere product is Allerdent™, specially formulated toothpaste that is easily and stably combined with immunotherapy allergens. Thus, a patient's daily immunotherapy administration can be seamlessly integrated with the ritual of daily tooth-brushing, a habitual lifelong healthcare behavior for most people. Allerdent™ has been developed to support long-term patient adherence to immunotherapy, which may result in more successful and long-lasting treatments. For more information, please visit http://www.allovate.com.
SOURCE Restore Health